Planned industry first clinical trial combining BeiGene's checkpoint inhibitor tislelizumab with Indaptus’ broadly targeted, short duration systemic immune stimulator Decoy20 expected to start in 2025 ...

PDS Biotechnology (PDSB) announced that the rationale and trial design for a study evaluating PDS01ADC for the treatment of recurrent prostate ...

Special Conference: Tumor Immunology and Immunotherapy: New immunology data showed ability of INO-3107 to induce an antigen-specific T cell response against HPV-6 and HPV-11 and drive recruitment of ...

Black men with advanced prostate cancer have a greater chance of survival after immunotherapy treatment, at least in part, because of ancestral gene variants in immune responses.

Researchers identified Janus kinase inhibitors as a promising treatment for the severe drug-induced skin condition toxic ...

According to a preclinical study conducted by Weill Cornell Medicine researchers it may soon be feasible to detect whether ...

Immune cells called monocytes produce a key inflammatory protein called interleukin-1 beta (IL-1β) through an unconventional ...

Acne is a skin condition characterized by clogged pores. When pores get clogged, it causes red lesions — which you know as ...

Lung cancer survival without treatment is shorter than survival with treatment. People with untreated non-small cell lung cancer—the most common type—typically live between 5 and 12 months after ...

According to a 2021 review, nail psoriasis can be challenging to treat, but treatment is possible. The best approach for you may depend on your specific symptoms and their severity. Keep reading ...

Hepatitis B virus (HBV) infection is a significant global health issue, affecting over 200 million people worldwide. Chronic HBV infection can lead to severe liver diseases such as cirrhosis and ...

Its severe form, metabolic dysfunction-associated steatohepatitis (MASH), can lead to liver fibrosis and even liver failure.